1. Home
  2. JELD vs BDSX Comparison

JELD vs BDSX Comparison

Compare JELD & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

HOLD

Current Price

$1.80

Market Cap

152.5M

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$16.78

Market Cap

153.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JELD
BDSX
Founded
1960
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Precision Instruments
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.5M
153.3M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
JELD
BDSX
Price
$1.80
$16.78
Analyst Decision
Hold
Strong Buy
Analyst Count
6
5
Target Price
$3.43
$32.50
AVG Volume (30 Days)
1.4M
48.8K
Earning Date
05-04-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,211,181,000.00
$88,499,000.00
Revenue This Year
N/A
$25.26
Revenue Next Year
$2.06
$19.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.08
52 Week Low
$0.93
$0.26
52 Week High
$6.98
$20.21

Technical Indicators

Market Signals
Indicator
JELD
BDSX
Relative Strength Index (RSI) 51.38 62.52
Support Level $1.64 $13.46
Resistance Level $2.15 $20.21
Average True Range (ATR) 0.19 1.00
MACD -0.03 0.00
Stochastic Oscillator 36.36 78.85

Price Performance

Historical Comparison
JELD
BDSX

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

Share on Social Networks: